Inclisiran - new hope in the management of lipid disorders?
Drugs reducing plasma concentrations of apolipoprotein-B (ApoB) containing lipoproteins have been demonstrated to reduce the risk of cardiovascular disease (CVD) in both primary and secondary prevention. Despite the demonstrated efficacy of statins and ezetimibe on low-density lipoprotein (LDL) concentration and long-term CVD risk, a large number of patients do not achieve their therapeutic goals. The introduction of monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) protein was a milestone in the treatment of lipid disorders, as their administration leads to unprecedentedly low LDL-C conce...
Source: Journal of Clinical Lipidology - November 12, 2019 Category: Lipidology Authors: Dyrbu ś Krzysztof, Gąsior Mariusz, Penson Peter, Ray Kausik K, Banach Maciej Tags: Review Article Source Type: research

National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High- or Very-high ASCVD Risk
Representatives from the National Lipid Association (NLA) participated in the development of the 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol, which reaffirmed that lifestyle changes and statin treatment are therapeutic cornerstones for atherosclerotic cardiovascular disease (ASCVD) risk reduction. It also updated prior recommendations to incorporate newer data demonstrating ASCVD risk reduction with ezetimibe and proprotein convertase subtilisin kexin type 9 inhibitors as adjuncts to statin therapy for patients at high and very high ASCVD risk...
Source: Journal of Clinical Lipidology - November 2, 2019 Category: Lipidology Authors: Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki Tags: Original Research Source Type: research

High-density Lipoprotein Cholesterol Efflux Capacity is not associated with Atherosclerosis and Prevalence of Cardiovascular Outcome: The CODAM Study
Cholesterol Efflux Capacity (CEC) is considered to be a key atheroprotective property of high-density lipoproteins (HDL). However, the role of HDL-CEC in atherosclerosis and cardiovascular (CV) risk is still controversial and data in individuals with diabetes are limited. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 31, 2019 Category: Lipidology Authors: Tatjana Josefs, Kristiaan Wouters, Uwe J.F. Tietge, Wijtske Annema, Robin P.F. Dullaart, Tomas Vaisar, Ilja C.W. Arts, Carla J.H. van der Kallen, Coen D.A. Stehouwer, Casper G. Schalkwijk, Ira J. Goldberg, Edward A. Fisher, Marleen M.J. van Greevenbroek Tags: Original Research Source Type: research

Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects
Fish oil enriched in omega-11 long-chain monounsaturated fatty acids (LCMUFA; C20:1 and C22:1 isomers combined) have shown lipid-lowering and atheroprotective effects in animal models. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 31, 2019 Category: Lipidology Authors: Zhi-Hong Yang, Marcelo Amar, Alexander V. Sorokin, James Troendle, Amber B. Courville, Maureen Sampson, Martin P. Playford, Shanna Yang, Michael Stagliano, Clarence Ling, Kwame Donkor, Robert D. Shamburek, Nehal N. Mehta, Alan T. Remaley Tags: Original Research Source Type: research

Colchicine's effects on lipoprotein particle concentrations in adults with metabolic syndrome: A secondary analysis of a randomized controlled trial
Colchicine has received renewed interest for its potential beneficial effects in secondary prevention of cardiovascular disease. This was presumed to be primarily because of its anti-inflammatory effects; however, limited data exist regarding colchicine's impact on other cardiovascular risk factors. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 22, 2019 Category: Lipidology Authors: Andrew P. Demidowich, Anna Wolska, Sierra R. Wilson, Jordan A. Levine, Alexander V. Sorokin, Sheila M. Brady, Alan T. Remaley, Jack A. Yanovski Tags: Original Article Source Type: research

Colchicine ’s Effects on Lipoprotein Particle Concentrations in Adults with Metabolic Syndrome: A Secondary Analysis of a Randomized Controlled Trial
Colchicine has received renewed interest for its potential beneficial effects in secondary prevention of cardiovascular disease. This has presumed to be primarily due to its anti-inflammatory effects; however, limited data exist regarding colchicine ’s impact on other cardiovascular risk factors. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 22, 2019 Category: Lipidology Authors: Andrew P. Demidowich, Anna Wolska, Sierra R. Wilson, Jordan A. Levine, Alexander V. Sorokin, Sheila M. Brady, Alan T. Remaley, Jack A. Yanovski Tags: Original Research Source Type: research

Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with PCSK9 gain-of-function or APOB loss-of-function mutations
Familial hypercholesterolemia (FH) is characterized by high levels of low-density lipoprotein cholesterol (LDL-C); causes of FH include apolipoprotein B (APOB) loss-of-function mutations (LOFm) and proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutations (GOFm). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 21, 2019 Category: Lipidology Authors: Paul N. Hopkins, Michel Krempf, Eric Bruckert, Stephen Donahue, Feng Yang, Yi Zhang, A. Thomas DiCioccio Tags: Original Research Source Type: research

Relationship between alirocumab, PCSK9, and LDL-C levels in four Phase 3 ODYSSEY trials using 75 and 150 mg doses
Alirocumab is a monoclonal antibody to PCSK9. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 14, 2019 Category: Lipidology Authors: Jennifer G. Robinson, Michel Farnier, John JP. Kastelein, Eli M. Roth, Marja-Riitta Taskinen, Helen M. Colhoun, Aurelie Brunet, A Thomas DiCioccio, Guillaume Lecorps, Robert Pordy, Marie T. Baccara-Dinet, Christopher P. Cannon Tags: Original Research Source Type: research

Niacin for Treatment of Nonalcoholic Fatty Liver Disease (NAFLD): Novel use for an old drug?
Niacin has been widely used clinically for over half a century for dyslipidemia. Recent new evidence indicates that niacin may be useful in the treatment of nonalcoholic fatty liver disease (NAFLD) and its sequential complications including nonalcoholic steatohepatitis (NASH), and fibrosis. There is an urgent unmet need for a cost-effective solution for this public health problem affecting nearly one in three adults. Niacin inhibits and reverses hepatic steatosis and inflammation in animals and liver cell cultures. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 14, 2019 Category: Lipidology Authors: Moti L. Kashyap, Shobha Ganji, Naresh K. Nakra, Vaijinath S. Kamanna Tags: Review Article Source Type: research

Measurement of Lipid Profiles in the Early Postpartum Period after Hypertensive Disorders of Pregnancy
The hypertensive disorders of pregnancy (HDP), comprised of preeclampsia (PE) and gestational hypertension (GHTN), are independent risk factors for future maternal cardiovascular disease (CVD). Epidemiologic evidence has demonstrated that women with HDP have abnormal cardiovascular (CV) risk factors in the early postpartum period, but this has not been fully characterized. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 12, 2019 Category: Lipidology Authors: Chuan Wen, Amy Metcalfe, Todd J. Anderson, Jo-Ann Johnson, Ronald J. Sigal, Kara A. Nerenberg Tags: Original Research Source Type: research

Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study
Maximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Little is known about the use of different statin regimens in FH. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 11, 2019 Category: Lipidology Authors: Leopoldo P érez de Isla, Raquel Arroyo-Olivares, Ovidio Muñiz-Grijalvo, José Luis Diaz-Díaz, Daniel Zambón, Francisco Fuentes, Juan F. Sánchez Muñoz-Torrero, Juan Diego Mediavilla, Aurora González-Estrada, Jose Pablo Miramontes-González, Raimundo Tags: Original Article Source Type: research

Effect of Evolocumab on Lipoprotein Apheresis Requirement and Lipid Levels: Results of the Randomized, Controlled, Open-Label DE LAVAL Study
Lipoprotein apheresis (LA) can effectively lower lipoproteins but is an invasive procedure. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 11, 2019 Category: Lipidology Authors: Seth J. Baum, Tiziana Sampietro, Dev Datta, Patrick M. Moriarty, Beat Knusel, Jingjing Schneider, Ransi Somaratne, Christopher Kurtz, Bernd Hohenstein Tags: Original Research Source Type: research

Long-term effect of two intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia. The SAFEHEART study.
Maximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Little is known about the use of different statin regimens in FH. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 11, 2019 Category: Lipidology Authors: Leopoldo P érez de Isla, Raquel Arroyo-Olivares, Ovidio Muñiz-Grijalvo, José Luis Diaz-Díaz, Daniel Zambón, Francisco Fuentes, Juan F. Sánchez Muñoz-Torrero, Juan Diego Mediavilla, Aurora González-Estrada, Jose Pablo Miramontes-González, Raimundo Tags: Original Research Source Type: research

Clinical and molecular genetic features of cerebrotendinous xanthomatosis in Taiwan: report of a novel CYP27A1 mutation and literature review
Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder associated with mutations in the CYP27A1 gene, and the genetic features of CTX in Taiwanese have not been examined before. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 10, 2019 Category: Lipidology Authors: Chia-Wei Lee, Jun-Jun Lee, Yen-Feng Lee, Pei-Wen Wang, Tai-Long Pan, Wen-Neng Chang, Meng-Han Tsai Tags: Original Research Source Type: research

Impact on Cardiometabolic Risk of a Weight Loss Intervention with Higher Protein from Lean Red Meat: Combined Results of Two Randomized Controlled Trials in Obese Middle-aged and Older Adults
The recognized benefits of a higher protein diet on muscle mass and strength in older adults are tempered by concerns of the potentially negative cardiometabolic impact of dietary sources of animal protein. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 2, 2019 Category: Lipidology Authors: Kathryn N. Porter Starr, Margery A. Connelly, Melissa Orenduff, Shelley R. McDonald, Richard Sloane, Kim M. Huffman, William E. Kraus, Connie W. Bales Tags: Original Research Source Type: research

LDL aggregation susceptibility is higher in healthy South Asian compared with white Caucasian men
South Asians are more prone to develop atherosclerotic cardiovascular disease (ASCVD) compared with white Caucasians, which is not fully explained by classical risk factors. We recently reported that the presence of aggregation-prone LDL in the circulation is associated with increased ASCVD mortality. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 30, 2019 Category: Lipidology Authors: Maija Ruuth, Laura G.M. Janssen, Lauri Äikäs, Feven Tigistu-Sahle, Kimberly J. Nahon, Olli Ritvos, Hanna Ruhanen, Reijo Käkelä, Mariëtte R. Boon, Katariina Öörni, Patrick C.N. Rensen Tags: Original Research Source Type: research

Coronary Artery Disease in a Child with Homozygous Familial Hypercholesterolemia: Regression after liver transplantation
Children with homozygous familial hypercholesterolemia are at risk for early cardiovascular events secondary to coronary artery disease. Current medical therapy does not ameliorate this risk. Liver transplantation offers the most effective option to reduce circulating levels of low-density lipoprotein cholesterol and thereby reduce risk of cardiovascular events. Angiographic evidence of regression of coronary artery disease is presented. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 25, 2019 Category: Lipidology Authors: Constance E. Cephus, Athar M. Qureshi, Mahboob Alam, Douglas S. Moodie Tags: Case Report Source Type: research

Type 1 Diabetes is Associated with an Increase in Cholesterol Absorption Markers but a Decrease in Cholesterol Synthesis Markers in a Young Adult Population
To optimize treatment and prevent cardiovascular disease in subjects with type 1 diabetes, it is important to determine how cholesterol metabolism changes with type 1 diabetes. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 25, 2019 Category: Lipidology Authors: Ivana Semova, Amy E. Levenson, Joanna Krawczyk, Kevin Bullock, Kathryn A. Williams, R. Paul Wadwa, Amy S. Shah, Philip R. Khoury, Thomas R. Kimball, Elaine M. Urbina, Sarah D. de Ferranti, Franziska K. Bishop, David M. Maahs, Lawrence M. Dolan, Clary B. C Tags: Original Research Source Type: research

Autosomal Recessive Hypercholesterolemia: Case Report
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 23, 2019 Category: Lipidology Authors: Zaneta Petrulioniene, Urte Gargalskaite, Violeta Mikstiene, Rimvydas Norvilas, Egle Skiauteryte, Algirdas Utkus Tags: Case Report Source Type: research

Lipoprotein Apheresis for Lipoprotein(a) and Cardiovascular Disease
Elevated lipoprotein(a) (Lp(a)) is an independent risk factor for cardiovascular disease (CVD). In the United States (US), lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany utilizes LA therapy for patients with an Lp(a)> 60 mg/dL, normal LDL-C levels, and CVD. LA therapy in this population demonstrated a> 70% reduction in CVD events. In the US, LA is only approved for patients with elevated LDL-C levels, regardless of Lp(a) level. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 21, 2019 Category: Lipidology Authors: Patrick M. Moriarty, Jessica V. Gray, Lauryn K. Gorby Tags: Original Research Source Type: research

Pseudohypertriglyceridemia —Raising clinical awareness
We read with interest the letter by Pedro-Botet et  al. describing a classic case of “pseudohypertriglyceridemia” secondary to glycerol kinase deficiency (GKD).1 The authors highlight key characteristics frequently observed in such patients including male gender (strongest risk factor), longstanding hypertriglyceridemia unresponsive to treatmen t, absence of low high-density lipoprotein cholesterol (HDL-C), and a clear serum sample. Other clinical features suggesting pseudohypertriglyceridemia include lack of obesity and a discordant lipid profile, as total cholesterol values are often lower than expected,...
Source: Journal of Clinical Lipidology - September 17, 2019 Category: Lipidology Authors: James M. Backes, Thomas Dayspring, Patrick M. Moriarty Tags: Letter to the Editor Source Type: research

Pseudohypertriglyceridemia – raising clinical awareness
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 17, 2019 Category: Lipidology Authors: James M. Backes, Thomas Dayspring, Patrick M. Moriarty Tags: Letter to the Editor Source Type: research

A 16-year trend of etiology in acute pancreatitis: the increasing proportion of hypertriglyceridemia-associated acute pancreatitis and its adverse effect on prognosis
Acute pancreatitis (AP) is an acute inflammation of the pancreas which caused increasing global health and economic burden. Longitudinal trends of disease etiology and its influence on prognosis remains unclear. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 16, 2019 Category: Lipidology Authors: Meng Jin, Xiaoyin Bai, Xuanfu Chen, Huimin Zhang, Bo Lu, Yi Li, Yamin Lai, Jiaming Qian, Hong Yang Tags: Original Research Source Type: research

Screening for Hyperglycerolemia by Triglyceride Assay in Urine
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 14, 2019 Category: Lipidology Authors: Jacinto Fern ández-Pardo, José L. Quílez-Fernández, Juan Pedro-Botet Tags: Letter to the Editor Source Type: research

Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force
Historically, low-carbohydrate (CHO) and very-low-CHO diets have been used for weight loss. Recently, these diets have been promoted for type II diabetes management. This scientific statement provides a comprehensive review of the current evidence base available from recent systematic reviews and meta-analyses on the effects of low-CHO and very-low-CHO diets on body weight, lipoprotein lipids, glycemic control, and other cardiometabolic risk factors. In addition, evidence on emerging risk factors and potential safety concerns of low-CHO and very-low-CHO diets, especially for high-risk individuals, such as those with geneti...
Source: Journal of Clinical Lipidology - September 13, 2019 Category: Lipidology Authors: C.F. Kirkpatrick, J.P. Bolick, P.M. Kris-Etherton, G. Sikand, K.E. Aspry, D.E. Soffer, K.E. Willard, K.C. Maki Tags: Original Research Source Type: research

In  vitro functional characterization of splicing variants of the APOB gene found in familial hypobetalipoproteinemia
Familial hypobetalipoproteinemia type 1 (FHBL-1) is a codominant disorder characterized by greatly reduced plasma levels of total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B. Rare exonic pathogenic variants of APOB gene (nonsense variants, minute deletions/insertions and nonsynonymous variants) have been frequently reported in subjects with FHBL-1. Also, rare intronic variants of APOB located at intron/exon junctions and assumed to affect splicing have been reported. However, the pathogenicity of most of these intronic variants remains to be established. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 12, 2019 Category: Lipidology Authors: Claudio Rabacchi, Maria Luisa Simone, Livia Pisciotta, Enza Di Leo, Davide Bocchi, Antonello Pietrangelo, Sergio D'Addato, Stefano Bertolini, Sebastiano Calandra, Patrizia Tarugi Tags: Original Research Source Type: research

In vitro functional characterization of splicing variants of the APOB gene found in Familial Hypobetalipoproteinemia
Familial hypobetalipoproteinemia type 1 (FHBL-1) is a codominant disorder characterized by greatly reduced plasma levels of total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B. Rare exonic pathogenic variants of APOB gene (nonsense variants, minute deletions/insertions and nonsynonymous variants) have been frequently reported in subjects with FHBL-1. Also rare intronic variants of APOB located at intron/exon junctions and assumed to affect splicing have been reported. However the pathogenicity of most of these intronic variants remains to be established. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 12, 2019 Category: Lipidology Authors: Claudio Rabacchi, Maria Luisa Simone, Livia Pisciotta, Enza Di Leo, Davide Bocchi, Antonello Pietrangelo, Sergio D ’Addato, Stefano Bertolini, Sebastiano Calandra, Patrizia Tarugi Tags: Original Research Source Type: research

Comparing Remnant Lipoprotein Cholesterol Measurement Methods to Evaluate Efficacy of Ezetimibe/Statin vs Statin Therapy
—Elevated remnant-lipoprotein cholesterol (RLP-C) levels increase cardiovascular disease risk. However, RLP-C measurement methods are not standardized, leading to variations across studies. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 11, 2019 Category: Lipidology Authors: Peter P. Toth, Harold E. Bays, W Virgil Brown, Alberico L. Catapano, Michael H. Davidson, Michel Farnier, Joanne E. Tomassini, Erin Jensen, Adam B. Polis, Andrew M. Tershakovec Tags: Original Research Source Type: research

Association between dyslipidemia and plasma levels of branched-chain amino acids in the Japanese population without diabetes mellitus
Branched-chain amino acids (BCAAs) play a key role in energy homeostasis. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 11, 2019 Category: Lipidology Authors: Keiko Fukushima, Sei Harada, Ayano Takeuchi, Ayako Kurihara, Miho Iida, Kota Fukai, Kazuyo Kuwabara, Suzuka Kato, Minako Matsumoto, Aya Hirata, Miki Akiyama, Masaru Tomita, Akiyoshi Hirayama, Asako Sato, Chizuru Suzuki, Masahiro Sugimoto, Tomoyoshi Soga, Tags: Original Research Source Type: research

Addition of marine omega-3 fatty acids to statins in familial hypercholesterolemia does not affect in vivo or in vitro endothelial function
Pre-statin trials reported positive effects of omega-3 fatty acids (n-3 PUFA) in cardiovascular disease (CVD), whereas recent studies and meta-analyses have not reproduced these results. The effect of n-3 PUFA in patients with familial hypercholesterolemia (FH), a group with particularly high risk of CVD, is not well established. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 29, 2019 Category: Lipidology Authors: Liv Nesse Hande, Hilde Thunhaug, Terje Enebakk, Judith Ludviksen, Kristin Pettersen, Anders Hovland, Knut Tore Lappeg ård Tags: Original Research Source Type: research

The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs
Accurate identification of patients with statin-associated side effects (SASEs) is critical for health care systems to institute strategies to improve guideline-concordant statin use. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 9, 2019 Category: Lipidology Authors: Salim S. Virani, Julia M. Akeroyd, Sarah T. Ahmed, Chayakrit Krittanawong, Lindsey A. Martin, Jason Slagle, Glenn T. Gobbel, Michael E. Matheny, Christie M. Ballantyne, Laura A. Petersen Tags: Original Article Source Type: research

The Use of Structured Data Elements to Identify ASCVD Patients with Statin-Associated Side Effects. Insights from the Department of Veterans Affairs
Accurate identification of patients with statin-associated side effects (SASEs) is critical for health-care systems to institute strategies to improve guideline-concordant statin use. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 9, 2019 Category: Lipidology Authors: Salim S. Virani, Julia M. Akeroyd, Sarah T. Ahmed, Chayakrit Krittanawong, Lindsey A. Martin, Jason Slagle, Glenn T. Gobbel, Michael E. Matheny, Christie M. Ballantyne, Laura A. Petersen Source Type: research

Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans
In the general population, elevated triglyceride (TG) levels are an important risk factor for cardiovascular disease and mortality. However, in chronic kidney disease, the association of serum TGs with mortality is less clear. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 8, 2019 Category: Lipidology Authors: Melissa Soohoo, Hamid Moradi, Yoshitsugu Obi, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Elani Streja Tags: Original Research Source Type: research

Serum Triglycerides and Mortality Risk Across Stages of Chronic Kidney Disease in 2 million US Veterans
In the general population, elevated triglyceride levels are an important risk factor for cardiovascular disease and mortality. However, in chronic kidney disease, the association of serum triglycerides (TG) with mortality is less clear (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 8, 2019 Category: Lipidology Authors: Melissa Soohoo, Hamid Moradi, Yoshitsugu Obi, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Elani Streja Tags: Original Research Source Type: research

Rapid improvement in carotid adventitial angiogenesis and plaque neovascularization after rosuvastatin therapy in statin treatment –naïve subjects
Statin therapy can improve plaque stability. However, the time course of effects of statin on adventitial angiogenesis and plaque neovascularization has not been studied. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 3, 2019 Category: Lipidology Authors: Ruixue Du, Jianming Cai, Bao Cui, Hongmei Wu, Xue-Qiao Zhao, Ping Ye Tags: Original Article Source Type: research

Rapid improvement in carotid adventitial angiogenesis and plaque neovascularization following rosuvastatin therapy in statin-na ïve subjects
Statin therapy can improve plaque stability. However, the time course of effects of statin on adventitial angiogenesis and plaque neovascularization has not been studied. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - August 3, 2019 Category: Lipidology Authors: Ruixue Du, Jianming Cai, Bao Cui, Hongmei Wu, Xue-Qiao Zhao, Ping Ye Tags: Original Research Source Type: research

Serum concentration of full-length- and carboxy-terminal fragments of endothelial lipase predicts future cardiovascular risks in patients with coronary artery disease
Endothelial lipase (EL), a regulator of plasma high-density lipoprotein cholesterol (HDL-C), is secreted as a 68-kDa mature glycoprotein, and then cleaved by proprotein convertases. However, the clinical significance of the circulating EL fragments remains unclear. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 29, 2019 Category: Lipidology Authors: Manabu Nagao, Kazuya Miyashita, Kenta Mori, Yasuhiro Irino, Ryuji Toh, Tetsuya Hara, Ken-ichi Hirata, Masakazu Shinohara, Katsuyuki Nakajima, Tatsuro Ishida Tags: Original Research Source Type: research

RAB18 modulates autophagy in human stellate  cells
Macroautophagy (or autophagy) is a conserved degradative pathway that breaks down sequestered cytoplasmic proteins and organelles in specialized double-membrane compartments called autophagosomes that fuse with lysosomes. Several proteins orchestrate this process, specifically Rab GTPases that are master regulators of molecular trafficking. RAB18 GTPase, a known mediator of stellate cell activation, is known to modulate autophagic flux in fibroblasts. However, its role in autophagy is unexplored in hepatic stellate cells. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 25, 2019 Category: Lipidology Authors: Soumik BasuRay Tags: Original Research Source Type: research

RAB18 modulates autophagy in human stellate cells
Macroautophagy (or autophagy) is a conserved degradative pathway that breaks down sequestered cytoplasmic proteins and organelles in specialized double membrane compartments called autophagosomes that fuse with lysosomes. Several proteins orchestrate this process, specifically Rab GTPases that are master regulators of molecular trafficking. RAB18 GTPase, a known mediator of stellate cell activation is known to modulate autophagic flux in fibroblasts. However, its role in autophagy is unexplored in hepatic stellate cells (HSCs). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 25, 2019 Category: Lipidology Authors: Soumik BasuRay Tags: Original Research Source Type: research

PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads
Improved survival after a cardiovascular event has led to an expanding patient population at very high risk of recurrent events. Reduction in low-density lipoprotein cholesterol, and thus implicitly non –high-density lipoprotein cholesterol, to guideline-recommended goals is a key tenet of secondary prevention. Yet, standard-of-care treatment with statin (with or without ezetimibe) often leaves a high risk of preventable cardiovascular events. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), highly efficacious lipid-lowering treatments that confer reduction in cardiovascular events and death, clea...
Source: Journal of Clinical Lipidology - July 24, 2019 Category: Lipidology Authors: Lieven Annemans, Jane K. Stock, M. John Chapman Tags: Review Article Source Type: research

PCSK9 Inhibition, Atherosclerotic Cardiovascular Disease and Health Economics: Challenges at the Crossroads
Improved survival following a cardiovascular event has led to an expanding patient population at very high risk of recurrent events. Reduction in low-density lipoprotein cholesterol, and thus implicitly non-high-density lipoprotein cholesterol, to guideline-recommended goals is a key tenet of secondary prevention. Yet, standard of care treatment with statin (with or without ezetimibe) often leaves a high risk of preventable cardiovascular events. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), highly efficacious lipid lowering treatments that confer reduction in cardiovascular events and death, clearly...
Source: Journal of Clinical Lipidology - July 24, 2019 Category: Lipidology Authors: Lieven Annemans, Jane K. Stock, M. John Chapman Tags: Review Article Source Type: research

The Economic Burden of Hypertriglyceridemia Among US Adults With Diabetes or Atherosclerotic Cardiovascular Disease on Statin Therapy
Hypertriglyceridemia (HTG) is associated with increased cardiovascular disease (CVD) risk. However, the cost burden of HTG-related CVD in high-risk US adults on statins has not been well characterized. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 20, 2019 Category: Lipidology Authors: Brian C. Case, Adam P. Bress, Paul Kolm, Sephy Philip, Jennifer S. Herrick, Craig B. Granowitz, Peter P. Toth, Wenjun Fan, Nathan D. Wong, Michael Hull, William S. Weintraub Tags: Original Research Source Type: research

The association of plasma lipids with white blood cell counts: Results from the Multi-Ethnic Study of Atherosclerosis
Previous studies have demonstrated that elevated cholesterol results in increased white blood cell counts in mouse models. However, there is insufficient evidence to support this in humans. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 15, 2019 Category: Lipidology Authors: Yong Chang Lai, Kevin J. Woollard, Robyn L. McClelland, Matthew A. Allison, Kerry-Anne Rye, Kwok Leung Ong, Blake J. Cochran Tags: Original Research Source Type: research

Translating plasma eicosapentaenoic acid concentrations into erythrocyte percentages of eicosapentaenoic acid plus docosahexaenoic acid during treatment with icosapent ethyl
The Reduction of Cardiovascular Events with Icosapent Ethyl –Intervention Trial (REDUCE-IT) study demonstrated that 4 g/d of eicosapentaenoic acid (EPA) ethyl esters (icosapent ethyl [IPE]) reduced risk for major cardiovascular events by 25% in statin-treated patients with residual hypertriglyceridemia. How this treatment affected red blood cell (RBC) EPA and docosahexaenoic acid (DHA) levels (ie, the Omega-3 Index [O3I]) was not reported, but effects on plasma EPA concentrations were reported. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 12, 2019 Category: Lipidology Authors: William S. Harris, Kristina H. Jackson Tags: Original Article Source Type: research

Translating plasma eicosapentaenoic acid (EPA) concentrations into erythrocyte percentages of EPA plus docosahexaenoic acid (DHA) during treatment with icosapent ethyl
The REDUCE-IT study demonstrated that 4 g/day of eicosapentaenoic acid (EPA) ethyl esters (icosapent ethyl, IPE) reduced risk for major cardiovascular events by 25% in statin-treated patients with residual hypertriglyceridemia. How this treatment affected red blood cell (RBC) EPA and docosahexaenoic acid (DHA) levels (i.e., the omega-3 index, O3I) was not reported, but effects on plasma EPA concentrations were. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 12, 2019 Category: Lipidology Authors: William S. Harris, Kristina H. Jackson Tags: Original Research Source Type: research

Impact of Improved Low-Density Lipoprotein Cholesterol Assessment on Guideline Classification in the Modern Treatment Era – Results from a Racially Diverse Brazilian Cross-Sectional Study
The Martin/Hopkins low-density lipoprotein cholesterol equation (LDL-CN) was previously demonstrated as more accurate than Friedewald estimation (LDL-CF) in a North American database not able to take race into account. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 9, 2019 Category: Lipidology Authors: Vincent A. Pallazola, Vasanth Sathiyakumar, Oluseye Ogunmoroti, Oluwaseun Fashanu, Steven R. Jones, Raul D. Santos, Peter P. Toth, Marcio S. Bittencourt, Bruce B. Duncan, Paulo A. Lotufo, Isabela M. Bensenor, Michael J. Blaha, Seth S. Martin Tags: Original Research Source Type: research

Mortality reduction with PCSK9 inhibition: A  case of cautious optimism
The advent of monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) has been a great achievement in clinical lipidology and cardiovascular medicine. Both alirocumab and evolocumab have been shown to significantly reduce cardiovascular events and are generally well tolerated, even in patients who achieve very low levels of low-density lipoprotein cholesterol (LDL-C).1,2 A question that remains unclear, however, is whether these therapies reduce mortality in high-risk patients on background statin therapy. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 4, 2019 Category: Lipidology Authors: Dave L. Dixon, Salim S. Virani Tags: Editorial Source Type: research

Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels
Cardiovascular disease (CVD) is a major cause of mortality and morbidity. Increased low-density lipoprotein-cholesterol (LDL-C) level is its major risk factor. Familial Hypercholesterolemia (FH) is a genetic disorder characterized by elevated LDL-C since birth and subsequent premature CVD. There is a heterogeneity in the CVD onset in FH patients. This is potentially due to the presence of other independent risk factors. Lipoprotein(a) [Lp(a)] is an LDL-like particle and represents a strong risk factor for CVD. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 4, 2019 Category: Lipidology Authors: Chiara Pavanello, Carlo Pirazzi, Kristina Bjorkman, Joakim Sandstedt, Claudia Tarlarini, Lorena Mosca, Stefano Romeo, Laura Calabresi, Rosellina Margherita Mancina Source Type: research

Mortality Reduction with PCSK9 Inhibition: A Case of Cautious Optimism
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 4, 2019 Category: Lipidology Authors: Dave L. Dixon, Salim S. Virani Tags: Editorial Source Type: research

PCSK9 Inhibition in Patients with Heart Transplantation: A Case Series
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - July 3, 2019 Category: Lipidology Authors: Pratik B. Sandesara, Devinder Dhindsa, Benjamin Hirsh, Maan Jokhadar, Robert T. Cole, Laurence S. Sperling Source Type: research